Half Year 2024 Imricor Medical Systems Inc Earnings Call Transcript
Key Points
- Imricor Medical Systems Inc (ASX:IMR) reported a 105% increase in total revenues for the first half of 2024 compared to the prior corresponding period.
- The company received Saudi FDA approval for its capital equipment and consumables, expanding its market reach.
- CE Mark approval was granted for the Vision MRI diagnostic catheter, the first to go through the new European Union's medical device regulation process.
- Significant milestones achieved include the first iCMR guided procedures in the US at Johns Hopkins and the commencement of procedures at multiple new international sites.
- The company completed two equity placements and a rights offering, resulting in gross proceeds of approximately $9.8 million, with additional capital raising initiatives expected to fund operations into 2026.
- Despite revenue growth, Imricor Medical Systems Inc (ASX:IMR) reported a net loss of $6.9 million for the period, though this was a decrease from the prior corresponding period.
- Operating cash outflow for the half year amounted to approximately $8 million, an increase of $1.8 million compared to the prior corresponding period.
- R&D spend decreased by $126,000, primarily due to reductions in regulatory spending and staffing costs, which could impact future innovation.
- The company is still in the process of gaining FDA approval for its VISABL-AFL trial, with significant milestones yet to be achieved.
- The first VT ablation trial has been delayed to early Q4 due to additional submissions to the ethics committee, pushing back expected timelines.
Morning and welcome to Imricor's first-half investor presentation, which will be released on the ASX imminently from the company. We have the CEO and President and Founder, Steve Waden; and the company's CFO, Jonathan Gut, and the Company's Chief Strategy Officer, Nick Corkill.
(Operator Instructions) Steve, I'll hand it over to you.
Thanks, Simon. And good morning, everyone. Welcome to Imricor's first-half FY24 fiscal financial results briefing.
I'm more excited, I got to say, today about the next 12 months at Imricor than I have been at any point since I started this company. And the very reason I started Imricor was to do complex ablations like VT and the iCMR lab and also to launch this technology across the US. And now we're entering this exciting chapter with the strongest balance sheet in our company's history, and I'm grateful for the support of our new and existing shareholders helping us deliver this important technology to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
